Palonosetron in the prevention of CINV (chemotherapy-induced nausea and vomiting) in Italy: Pharmacological, clinical and pharmacoeconomic aspects;Palonosetron nella prevenzione della CINV in Italia: Aspetti farmacologici, clinici e farmacoeconomici

Tumori

Volumn 94, Issue 2, 2008, Pages 26-32

  Pradelli, Lorenzo ^a   Eandi, Mario ^b  

^a Advanced Research Srl   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PACLITAXEL; PALONOSETRON; TROPISETRON;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; DRUG RECEPTOR BINDING; ECONOMIC ASPECT; HEALTH CARE COST; HUMAN; ITALY; NAUSEA AND VOMITING; NEOPLASM; PROPHYLAXIS; QUALITY OF LIFE;

ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COST-BENEFIT ANALYSIS; DRUG COSTS; GRANISETRON; HUMANS; INDOLES; ISOQUINOLINES; ITALY; NAUSEA; ONDANSETRON; PRIMARY PREVENTION; QUINOLIZINES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; VOMITING;

EID: 45249083646     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM et al: American Society of Clinical Oncology guideline for antiemetics in oncology. J Clin Oncol 2006; 24: 2932-2945.
2. Dando TM, Perry CM: Aprepitant. A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-797.
3. Gruppo di lavoro ETEO: Epidemiologia dei trattamenti dell'emesi in oncologia. Giornale Italiano di Farmacologia Clinica 2005; 19: 359-365.
4. Eisenberg PD, Rubenstein EB, Cohen L, De Moor C, Kim YJ, Grunberg SM: Perceptions and satisfaction of oncologists and oncology nurses of antiemetic therapy for CINV vs patients experiences after emetogenic chemotherapy in the US. Proc ASCO 2003; abstr 2974.
5. De Moor C, Cohen L, Eisenberg PD, Grunberg SM, Kim YJ, Rubenstein EB: Oncologists' compliance with antiemetic guidelines and outcomes of patients receiving emetogenic chemiotherapy. Proc ASCO 2003; abstr 2924.
6. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J: Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5 (4): 307-313.
7. Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D: Measuring chemotherapy-induced nausea and emesis. Cancer 2003; 98: 645-655.
8. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW et al: Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005; 13: 219-227.
9. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C et al: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14: 1570-1577.
10. Eisenberg P, Figueroa-Vadillo J, Zamora R, Cham V, Hajdenberg J, Cartmell A et al: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98: 2473-2482.
11. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17: 1441-1449.
12. EMEA: EPARs for authorised medicinal products for human use: Aloxi, H-C-563, Scientific discussion. Disponibile all'indirizzo web http://www.emea.europa.eu/humandocs/Humans/EPAR/aloxi/aloxi.htm, consultato il 12 luglio 2007.
13. Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G et al: The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 2007; 15: 31-38.
14. Prontuario Farmaceutico Nazionale: Farmaci Classi A e H. Determinazione AIFA 9/02/2007, prezzi disponibili agli indirizzi www.agenziafarmaco.it/aifa/ servlet/wscs_render_attachment_by_id/111.84470.1172743348645.pdf?id=111.81951. 1172658490314 e www.agenziafarmaco.it/aifa/servlet/wscs_render_attachment_by_id/ l 11.84521.1172743415144.pdf?id=111.81900.1172658424870
15. Tarricone R, Girolami F: Economic evaluation of a new antiemetic drug. Palonosetron versus ondansetron: assessment of the drug price ratio in five European countries. Clin Drug Investig 2005; 25: 597-608.
16. 3 inibitori di prima generazione. PharmacoEconomics Italian Research Articles 2006; 8: 1-10.